Literature DB >> 6587917

Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells.

D Kufe, D Spriggs, E M Egan, D Munroe.   

Abstract

Cytosine arabinoside (Ara-C) is the most effective agent in the treatment of acute myelogenous leukemia. This agent incorporates in leukemic cell DNA, and the extent of this incorporation correlates with loss of clonogenic survival. The incorporated Ara-C residue behaves as a relative DNA chain terminator, and the extent of (Ara-C)DNA formation correlates with inhibition of DNA synthesis. The incorporation of Ara-C into DNA requires the formation of Ara-CTP, and previous measurements of this metabolite have also been correlated with cytotoxicity. Because it is clinically relevant to define biochemical parameters predictive of Ara-C cytotoxicity, the present studies were undertaken to determine the relationship among Ara-CTP pools, formation of (Ara-C)DNA, and loss of clonogenic survival. The results demonstrate that the incorporation of Ara-C into DNA is the single most powerful predictor of cell lethality. Furthermore, although there is a correlation between Ara-CTP pools or continuous cellular exposure to Ara-CTP and cell kill, these relationships are less significant than that obtained with formation of (Ara-C)DNA. The extent of Ara-C incorporation into DNA can be predicted by the product of the Ara-CTP level and time (T), thus supporting the concept that Ara-C incorporation is dependent on continuous exposure to the triphosphate metabolite. These findings support the formation of (Ara-C)DNA as a highly predictive parameter of lethal cellular events.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

Authors:  R L Momparler; N Onetto-Pothier; D Y Bouffard; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 3.  A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Authors:  R J Fram
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

4.  Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Authors:  Nikolas Herold; Sean G Rudd; Linda Ljungblad; Kumar Sanjiv; Ida Hed Myrberg; Cynthia B J Paulin; Yaser Heshmati; Anna Hagenkort; Juliane Kutzner; Brent D G Page; José M Calderón-Montaño; Olga Loseva; Ann-Sofie Jemth; Lorenzo Bulli; Hanna Axelsson; Bianca Tesi; Nicholas C K Valerie; Andreas Höglund; Julia Bladh; Elisée Wiita; Mikael Sundin; Michael Uhlin; Georgios Rassidakis; Mats Heyman; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Julian Walfridsson; Sören Lehmann; Dan Grandér; Thomas Lundbäck; Per Kogner; Jan-Inge Henter; Thomas Helleday; Torsten Schaller
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

5.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

Review 6.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

7.  Use of the circuit simulation program SPICE2 for analysis of the metabolism of anticancer drugs.

Authors:  J C White
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

8.  A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and -resistant leukemic cells.

Authors:  L P Colly; D J Richel; W Arentsen-Honders; I W Starrenburg; P M Edelbroek; R Willemze
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.

Authors:  M R Motta; M Baccarani; S Rizzi; R Fanin; G Fasola; C Poluzzi; S Tura
Journal:  Blut       Date:  1987-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.